Premium
Effect of recombinant human transforming growth factor‐β2 dose on bone formation in rat femur titanium implant model
Author(s) -
Sena Kotaro,
Sumner Dale R.,
Virdi Amarjit S.
Publication year - 2009
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.32461
Subject(s) - implant , fixation (population genetics) , femur , materials science , titanium , biomedical engineering , histology , dentistry , medicine , surgery , metallurgy , population , environmental health
Previously, we reported that application of 10 μg recombinant human TGF‐β2 (rhTGF‐β2) enhanced peri‐implant bone formation and bone‐implant contact in a rat model. To further investigate the dose effect, the present experiment evaluated doses of rhTGF‐β2 bracketed around 10 μg (5, 10, 20 μg) using the same model. Four groups (including buffer‐only control) received femoral implantation of hydroxyapatite/tricalcium phosphate‐coated titanium implants. Four weeks post‐surgery, all femurs were collected and analyzed by micro computed tomography followed by a mechanical test or histology. Compared with control, all rhTGF‐β2‐treated groups had significantly higher bone volume. Bone‐implant contact was not different between the control, 5, and 10 μg groups; however, the 20 μg group had less contact than the control. There were significant decreases in the strength of fixation in all rhTGF‐β2 treated groups compared with the control. In particular, while rhTGF‐β2 was able to enhance bone formation in the vicinity of the implant, the relative lack of bone‐implant contact in the 20 μg group depressed the strength of fixation, suggesting that the location as well as the amount of new bone formed is important for implant fixation. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010